|Company||RetroSense Therapeutics, LLC
|Funded by Foundation Fighting Blindness / National Neurovision Research Institute, private investors, Michigan Economic Development Corporation
||Retinal degenerative conditions|
|Significant Unmet Medical Need||In spite of decades of research and development efforts, there are currently no FDA approved therapies for the treatment of either retinitis pigmentosa or dry age-related macular degeneration. There are currently 100k people with retinitis pigmentosa and 1 million with advanced dry age-related macular degeneration in the US.
||Actively seeking partnerships and collaborations|
||Ann Arbor, Michigan|